Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 7/20 | 0.34 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 4/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.32 |
| ▸ | CDK2 | P24941 | 3/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.32 |
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6715903 | 0.81 | TRPA1 (0.35) | LMNACYP1A2ALOX5CCNE1CDK2 | |
| SCHEMBL7257113 | 0.81 | CDK2 (0.38) | LMNACYP1A2ALOX5CCNE1CDK2 | |
| SCHEMBL27572548 | 0.81 | CDK2 (0.38) | LMNACYP1A2ALOX5CCNE1CDK2 | |
| SCHEMBL27570619 | 0.81 | CDK2 (0.38) | ALOX5CCNE1CDK2CDK5MLYCD | |
| SCHEMBL6758493 | 0.80 | NPC1 (0.39) | KDM4ELMNAALOX5NPC1RAB9A | |
| SCHEMBL27574287 | 0.80 | CCNE1 (0.37) | ALOX5CCNE1CDK2CDK5MLYCD | |
| SCHEMBL6710898 | 0.80 | MLYCD (0.38) | ALOX5CCNE1CDK2CDK5MLYCD | |
| SCHEMBL6711707 | 0.80 | MLYCD (0.47) | LMNACYP1A2ALOX5NPC1RAB9A | |
| SCHEMBL6712094 | 0.79 | ALDH1A1 (0.38) | KDM4ELMNACCNE1CDK2CDK5 | |
| SCHEMBL6712093 | 0.79 | MAOA (0.35) | KDM4ELMNAALOX5CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1325390-A | 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2001-12-05 | — | — | CN | claimed |
| US-20040157827-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PEVARELLO PAOLO (IT) | 2004-08-12 | — | — | US | disclosed |
| US-20030187040-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2003-10-02 | — | — | US | disclosed |
| CN-1325390-A | 2-ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | PHARMACIA & UPJOHN SPA (IT) | 2001-12-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187040-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | UCK2, ULK3, CDK2 | KDM4E 2087/4885LMNA 1246/4885POLB 2499/4885 |
| US-20040157827-A1 | 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents | UCK2, ULK3, CDK2 | KDM4E 2087/4885LMNA 1246/4885POLB 2499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.